このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

DRCR.Net アフリベルセプト vs. ベバシズマブ + 延期されたアフリベルセプトによる CI-DME の治療 (DRCR AC)

2026年9月9日 更新者:Jaeb Center for Health Research

中枢性糖尿病性黄斑浮腫の治療のための硝子体内アフリベルセプト対硝子体内ベバシズマブ + 延期アフリベルセプトのランダム化試験

Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes. However, aflibercept was shown to be more effective at improving vision, on average, at 1 year and at 2 years. Due to the large cost difference between the two drugs, many clinicians and patients are choosing to initiate treatment with bevacizumab and then switch to aflibercept depending on the eye's response to bevacizumab treatment. However, there is no scientific evidence that this treatment strategy is as effective at improving vision as initiating treatment with aflibercept. Patients and clinicians do not know if this approach ultimately has deleterious effects on visual acuity. If starting with aflibercept is not better than starting with bevacizumab and switching to aflibercept if needed, the potential cost savings to future patients and the health care system would be substantial. However, if starting with aflibercept is better, then patients, clinicians, and health care providers can make informed decisions for how to best treat patients with DME and at least moderate vision loss.

Study Objectives To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss

調査の概要

研究の種類

介入

入学 (実際)

270

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Campbell、California、アメリカ、95008
        • Retinal Diagnostic Center
      • Glendale、California、アメリカ、91203
        • Macula & Retina Institute
      • Loma Linda、California、アメリカ、92354
        • Loma Linda University Health Care, Department of Ophthalmology
      • Oakland、California、アメリカ、94609-3028
        • East Bay Retina Consultants, Inc
    • Florida
      • Fort Myers、Florida、アメリカ、33912
        • National Ophthalmic Research Institute
      • Jacksonville、Florida、アメリカ、32216
        • Florida Retina Institute-Jacksonville
      • Lakeland、Florida、アメリカ、33805
        • Florida Retina Consultants
      • Miami、Florida、アメリカ、33126
        • Retina Macula Specialists of Miami
      • Orlando、Florida、アメリカ、32806
        • Florida Retina Institute
      • Orlando、Florida、アメリカ、32806
        • Central Florida Retina
      • Pinellas Park、Florida、アメリカ、33782
        • Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
      • Plantation、Florida、アメリカ、33324
        • Fort Lauderdale Eye Institute
      • Sarasota、Florida、アメリカ、34239
        • Sarasota Retina Institute
      • Sarasota、Florida、アメリカ、34233
        • Retina Associates of Sarasota
      • Tampa、Florida、アメリカ、33609
        • Retina Associates of Florida, LLC
      • Wesley Chapel、Florida、アメリカ、33544
        • Retina Specialists of Tampa
    • Georgia
      • Augusta、Georgia、アメリカ、30909
        • Southeast Retina Center, P.C.
      • Sandy Springs、Georgia、アメリカ、30328
        • Thomas Eye Group
    • Illinois
      • Oak Park、Illinois、アメリカ、60304
        • Illinois Retina Associates, S.C.
      • Springfield、Illinois、アメリカ、62703
        • Springfield Clinic, LLP
    • Indiana
      • Indianapolis、Indiana、アメリカ、46290
        • Raj K. Maturi, M.D., P.C.
      • New Albany、Indiana、アメリカ、47150
        • John-Kenyon American Eye Institute
    • Kansas
      • Overland Park、Kansas、アメリカ、66211
        • Mid-America Retina Consultants, P.A.
      • Shawnee Mission、Kansas、アメリカ、66204
        • Retina Associates, P.A.
    • Kentucky
      • Paducah、Kentucky、アメリカ、42001
        • Paducah Retinal Center
    • Louisiana
      • West Monroe、Louisiana、アメリカ、71291
        • Eye Associates of Northeast Louisiana dba Haik Humble Eye Center
    • Maryland
      • Hagerstown、Maryland、アメリカ、21740
        • Mid Atlantic Retina Specialists
    • Massachusetts
      • Ayer、Massachusetts、アメリカ、01432
        • Valley Eye Physicians and Surgeons
      • Boston、Massachusetts、アメリカ、02215
        • Joslin Diabetes Center
    • Michigan
      • Grand Rapids、Michigan、アメリカ、49546
        • Vitreo-Retinal Associates
      • Grand Rapids、Michigan、アメリカ、49546
        • Retina Specialists of Michigan
    • Missouri
      • St Louis、Missouri、アメリカ、63128
        • The Retina Institute
    • New Mexico
      • Albuquerque、New Mexico、アメリカ、87109
        • Eye Associates of New Mexico
    • New York
      • New York、New York、アメリカ、10021
        • MaculaCare
      • Rochester、New York、アメリカ、14620
        • Retina Associates of Western New York
    • North Carolina
      • Asheville、North Carolina、アメリカ、28803
        • Western Carolina Clinical Research, LLC
      • Charlotte、North Carolina、アメリカ、28210
        • Charlotte Eye, Ear, Nose and Throat Assoc., PA
    • Ohio
      • Cleveland、Ohio、アメリカ、44106
        • University Hospitals Cleveland Medical Center
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73104
        • Dean A. McGee Eye Institute
    • Oregon
      • Portland、Oregon、アメリカ、97221
        • Retina Northwest, PC
      • Springfield、Oregon、アメリカ、97477
        • Cascade Medical Research Institute, LLC
    • Pennsylvania
      • Monroeville、Pennsylvania、アメリカ、15146
        • Retina Vitreous Consultants
      • Philadelphia、Pennsylvania、アメリカ、19107-5109
        • Retinavitreous Associates, dba; Mid Atlantic Retina
    • Tennessee
      • Knoxville、Tennessee、アメリカ、37909
        • Southeastern Retina Associates, P.C.
    • Texas
      • Austin、Texas、アメリカ、78705
        • Austin Retina Associates
      • Austin、Texas、アメリカ、78705
        • Retina Research Center
      • Grapevine、Texas、アメリカ、76051
        • Retina Center of Texas
      • Houston、Texas、アメリカ、77030
        • Retina Consultants of Houston, PA
      • Houston、Texas、アメリカ、77030
        • Baylor Eye Physicians and Surgeons
      • Lubbock、Texas、アメリカ、79424
        • Texas Retina Associates
      • McAllen、Texas、アメリカ、78503
        • Valley Retina Institute
      • San Antonio、Texas、アメリカ、78240
        • Retinal Consultants of San Antonio
    • Washington
      • Spokane、Washington、アメリカ、99204
        • Spokane Eye Clinic
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • Medical College of Wisconsin

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Participant-level Criteria Inclusion

To be eligible, the following inclusion criteria must be met:

  1. Age ≥ 18 years • Individuals <18 years old are not being included because DME is so rare in this age group that the diagnosis of DME may be questionable.

  2. Diagnosis of diabetes mellitus (type 1 or type 2)

    • Any one of the following will be considered to be sufficient evidence that diabetes is present:

    Current regular use of insulin for the treatment of diabetes Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes Documented diabetes by American Diabetes Association and/or World Health Organization criteria

  3. At least one eye meets the study eye criteria listed.

  4. Able and willing to provide informed consent.

    Exclusion

    An individual is not eligible if any of the following exclusion criteria are present:

  5. Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.

  6. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).

    • Individuals in poor glycemic control who, within the last four months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next four months should not be enrolled.
  7. Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied at the time of study entry.

    • Note: study participants cannot receive another investigational drug while participating in the study.

  8. Known allergy to any component of the study drug or any drug used in the injection prep (including povidone iodine prep).

  9. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110).

    • If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.

  10. Systemic anti-VEGF or pro-VEGF treatment within four months prior to randomization or anticipated use during the study.

    • These drugs cannot be used during the study.

  11. For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 24 months.

    • Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.

  12. Individual is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the next two years.

Study Eye Criteria The study participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below.

Study participants can have two study eyes only if both eyes are eligible at the time of randomization. For study participants with two eligible eyes, the logistical complexities of the protocol must be considered for each individual prior to randomizing both eyes.

The eligibility criteria for a study eye are as follows:

Inclusion

  1. Best corrected Electronic-Early Treatment Diabetic Retinopathy Study visual acuity letter score < 69 (i.e., 20/50 or worse) and ≥ 24 (i.e., 20/320 or better) within eight days of randomization.

  2. On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula.

  3. Diabetic macular edema present on optical coherence tomography (OCT) within eight days of randomization

    • Zeiss Cirrus central subfield: ≥ 290µm in women or ≥ 305µm in men
    • Heidelberg Spectralis central subfield: ≥ 305µm in women or ≥ 320µm in men
    • Investigator must verify accuracy of OCT scan by ensuring it is centered and of adequate quality
  4. Media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus photographs.

    Exclusions

    The following exclusions apply to the study eye only (i.e., they may be present for the nonstudy eye):

  5. Macular edema is considered to be due to a cause other than diabetic macular edema.

    • An eye should not be considered eligible if: (1) the macular edema is considered to be related to ocular surgery such as cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema.

  6. An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).

  7. An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).

  8. Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by three lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).

  9. History of an anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) in the past 12 months or history of any other treatment for DME at any time in the past four months (such as focal/grid macular photocoagulation, intravitreous or peribulbar corticosteroids).

    • Enrollment will be limited to a maximum of 25% of the planned sample size with any history of anti-VEGF treatment for DME. Once this number of eyes has been enrolled, any history of anti-VEGF treatment for DME will be an exclusion criterion.

  10. History of pan-retinal photocoagulation within four months prior to randomization or anticipated need for pan-retinal photocoagulation in the six months following randomization.

  11. History of anti-VEGF treatment for a disease other than DME in the past 12 months.

  12. History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior four months or anticipated within the next six months following randomization.

  13. History of YAG capsulotomy performed within two months prior to randomization.

  14. Aphakia.

  15. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.

  16. Evidence of uncontrolled glaucoma. • Intraocular pressure must be <30, with no more than one topical glaucoma medication, and no documented glaucomatous field loss for the eye to be eligible

Note, combination therapies are considered more than one medication

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Aflibercept Group

2.0 mg intravitreous aflibercept

Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.

Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.

Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using sterile technique

他の名前:
  • アイリーア
実験的:Bevacizumab + Deferred Aflibercept Group

1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria

Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.

Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.

Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using sterile technique

他の名前:
  • アイリーア

Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.

Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.

Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using a sterile technique.

他の名前:
  • アバスチン

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Mean Change in Visual Acuity
時間枠:2 years

Area under the curve mean change in the electronic early treatment diabetic retinopathy study visual acuity. Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up.

2 years

二次結果の測定

結果測定
メジャーの説明
時間枠
訪問数
時間枠:2年
2年
ベバシズマブ先行群の眼の数が切り替え基準を満たす
時間枠:ベースラインから 12 週間まで
ベースラインから 12 週間まで
ベバシズマブ先行群の眼の数が切り替え基準を満たす
時間枠:ベースラインから 24 週間まで
ベースラインから 24 週間まで
ベバシズマブ先行群の眼の数が切り替え基準を満たす
時間枠:ベースラインから52週間まで
ベースラインから52週間まで
ベバシズマブ先行群の眼の数が切り替え基準を満たす
時間枠:ベースラインから 104 週間まで
ベースラインから 104 週間まで
Change in Visual Acuity From Baseline
時間枠:2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Increase in E-ETDRS Visual Acuity Letter Score
時間枠:2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Decrease in E-ETDRS Visual Acuity Letter Score
時間枠:2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Visual Acuity
時間枠:2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Optical Coherence Tomography Central Subfield Thickness Change From Baseline
時間枠:2 years

Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.

2 years
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema
時間枠:2 years

Optical coherence tomography (OCT) central subfield thickness equivalents for measurements obtained on Spectral domain OCT machines were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus OCT measurement device (Zeiss).

2 years
Number of Injections
時間枠:2 years

All study injections were counted, including aflibercept injections received among eyes in the bevacizumab first group.

2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年12月7日

一次修了 (実際)

2021年12月22日

研究の完了 (実際)

2021年12月22日

試験登録日

最初に提出

2017年10月23日

QC基準を満たした最初の提出物

2017年10月23日

最初の投稿 (実際)

2017年10月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月9日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する